Marealis’ novel shrimp peptide gains EFSA green light

Marealis’ novel shrimp peptide gains EFSA green light

22 May 2018 --- The European Food Safety Authority (EFSA) has approved an application for the novel food status of a shrimp peptide concentrate, meaning that the ingredient can now be utilized in EU supplement applications. The application was made by the company Medfiles Ltd. on behalf of Marealis, a developer of science-backed nutraceuticals. The supplements will be marketed to those who want to address the problem of prehypertension in the Marealis product, PreCardix.

“The EFSA approval means that we will now be able to start working on commercialization in Europe. It also means that all our regulatory processes are completed with huge success – receiving approvals from Health Canada, FDA and EFSA,” Andreas Semmingsen, Head of Market and Finance at Marealis tells NutritionInsight.

“We have strong documentation showing a significant blood pressure lowering effect from using PreCardix. In Canada, where we just started sales, we have an approval to use the following health claim: ‘Helps to Click to Enlargemaintain healthy blood pressure levels and to support cardiovascular health,’” Semmingsen adds.

Following a request from the European Commission, the EFSA panel of Dietetic Products, Nutrition and Allergies (NDA) were asked to deliver a scientific opinion on shrimp peptide concentrate as a novel food (NF). Marealis provided scientific studies and data on the shrimp peptides health benefits.

During the process, one key concern was the potential astaxanthin content of the product because shrimps are a natural source of this carotClick to Enlargeenoid, which gives them their reddish color. This concern was initially raised by The Finnish Food Safety Authority. 

However, the shrimp peptides were approved to be marketed to adults at the maximum proposed level of intake of 1,200 mg a day. There were no concerns with regard to genotoxicity, the available human data do not raise safety concerns and there were no considered adverse effects for oral toxicity. 

Marealis appear confident on the future path of the shrimp peptide as a novel food ingredient, with other geographic areas delivering positive results: “We just started sales in Canada, which was a huge milestone for us. We will now start to work on commercialization of PreCardix in Norway. We hope to be in the Norwegian supplement market by the end of 2018. Our plan is to start with the Norwegian marked and expand to other European countries eventually.”

Marealis is a Norwegian marine biotechnology company focusing on the development of novel bioactive peptides derived from sustainable sources of the Arctic Ocean.

By Laxmi Haigh
 

To contact our editorial team please email us at editorial@cnsmedia.com


Related Articles

FormattedPicture

NUTRITION & HEALTH NEWS

07 Mar 2019 --- Tetrahedron, which specializes in developing ingredients for the nutraceutical, pharmaceutical and personal care industries, has received Novel Food status from the... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

04 Mar 2019 --- High-fat diets rich in omega 6 fatty acids and aging are significant contributors to health risks ranging from diabetes to heart failure, according to a new study.... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

28 Feb 2019 --- Following a diet that encourages a healthy gut microbiome, avoiding central obesity and getting enough sleep are among the lifestyle factors that may help to... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

28 Feb 2019 --- While the EU production and marketing of food products derived from Cannabis sativa L. has been considerably restricted since cannabidiol (CDB) food products... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

11 Feb 2019 --- Contrary to popular belief, a higher intake of sodium can increase lightheadedness instead of alleviating it. This is according to a new study from the Beth Israel... Read More